Selumetinib granted US Breakthrough Therapy Designation in neurofibromatosis type 1
Designation based on Phase II SPRINT trial in paediatric patients with NF1 plexiform neurofibromas Selumetinib is a MEK 1/2 Inhibitor being co-developed by AstraZeneca and MSDAstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the MEK 1/2 inhibitor and potential new medicine selumetinib. This designation is for the treatment of paediatric patients aged three years and older with neurofibromatosis type 1 (NF1)